Despite some expression of folate receptor α in human mesothelioma cells, internalization of methotrexate is predominantly carrier mediated

Journal of Thoracic and Cardiovascular Surgery

Volumn 123, Issue 5, 2002, Pages 862-868

  Khokhar, Nushmia Z ^a   Lam, Alicia F Y ^a   Rusch, Valerie W ^a   Sirotnak, F M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID DERIVATIVE; FOLIC ACID RECEPTOR ALPHA; METHOTREXATE; RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; DRUG TRANSPORT; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNALIZATION; MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSPORT KINETICS;

EID: 0036587251     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1067/mtc.2002.120352     Document Type: Article

References (24)

1. Sirotnak FM. Obligate genetic expressing in tumor cells of a fetal membrane property mediating folate transport: biological significance and implications for improved therapy of human cancer. Cancer Res. 1985;45:3992-4000.
2. Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. In: Goldman ID, editor. Membrane transport of antineoplastic agents. Int Encycl Pharmacol Therapeutics. 1986;118:283-302.
3. Sirotnak FM, Tolner B. Carrier-mediated membrane transport of folates in mammalian cells. Ann Rev Nutr. 1999;19:91-122.
4. Ratnam M, Freisheim JH. Proteins involved in the transport of folates and antifolates by normal and neoplastic cells: In: Picriano MF, editor. Folate metabolism in health and disease. New York: Wiley-Liss; 1992. p. 91-120.
5. Kamen BA, Capdevila A. Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc Natl Acad Sci U S A. 1986;83:5983-7.
6. Anderson RG, Kamen BA, Rothberg KG. Potocytosis: sequestration and transport of small molecules by caveolae. Science. 1992;255:410-1.
7. Smart EJ, Foster DC, Ying YS, Kamen BA, Anderson RG. Protein kinase C activators inhibit receptor-mediated potocytosis by preventing internalization of caveolae. J Cell Biol. 1994;124:307-13.
8. Henderson GB, Tsuji JM, Kumar HP. Mediated uptake of folate by a high-affinity binding protein in sublines of L1210 cells adapted to nanomolar concentrations of folate. J Membr Biol. 1998;101:247-58.
9. Konig J, Nies AT, Cui Y, Leier I, Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity and MRP2-mediated drug resistance. Biochem Biophys Acta. 1999;1461:377-94.
10. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporers: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92:1295-302.
11. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. J Clin Oncol. 1996:14:1007-17.
12. Rusch VW. Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 1997;9:367-72.
13. Kindler HL, Belani CP, Herndon JE II, Vogelzang NJ, Suzuki Y, Green MR. Edatrexate (10-ethyl-deaza-aminopterin) (NSC:626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer. 1999;86:1985-91.
14. Bueno R, Appasani K, Mercer H, Lester S, Sugarbaker D. The α folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;121:225-33.
15. Sirotnak FM, DeGraw JI, Moccio DM, Goutas LJ. New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol. 1984;12:18-25.
16. Moccio DM, Sirotnak FM, Samuels LL, Ahmed T, Yagoda A, DeGraw JI, et al. Similar specificity of membrane transport for folate analogues and their metabolites by murine and human tumor cells: a clinically directed laboratory study. Cancer Res. 1984;44:352-7.
17. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Danenberg PV, Laird PW. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res. 1999;59:2302-6.
18. Fink L, Seeger W, Ermert L, Hänze J, Stahl U, Grimminger F, et al. Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med. 1998;4:1329-33.
19. Yuan A, Yang PC, Yu CJ. Chen WJ, Lin FY, Kuo SH, et al. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med. 2000;162:1957-63.
20. User Bulletin #2: ABI Prism 7700 Sequence Detection System. Perkin Elmer Corp; P/N 4303859 Rev. A, Stock No. 777802-001, 1997.
21. Samuels LL, Moccio DM, Sirotnak FM. Similar differential for total polyglutamylation and cytotoxicity among various folate analogue in human and murine tumor cell lines in vitro. Cancer Res. 1985;45:488-95.
22. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer. 1997;74:193-8.
23. Corona G, Giannini F, Fabris M, Toffoli G, Boiocchi M. Role of folate receptor and reduced folate carrier in the transport of 5-methyltetrahydrofolic acid in human ovarian carcinoma cells. Int J Cancer. 1998;75:125-33.
24. Krug LM, Ng, KK, Kris MG, Miller VA, Tong W, Heelan RT, et al. Phase I and phaxmacokinetic study of 10-deazaaminopterin, a new antifolate. Clin Cancer Res. 2000;6:3493-8.